(VIANEWS) – The NASDAQ opens in less than two hours and NeuroMetrix‘s pre-market value is already 4.9% up.
NeuroMetrix’s last close was $1.43, 75.72% under its 52-week high of $5.89.
The last session, NASDAQ ended with NeuroMetrix (NURO) rising 2.14% to $1.43. NASDAQ rose 0.76% to $12,087.96, following the last session’s upward trend on what was a somewhat positive trend trading session.
About NeuroMetrix
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
Earnings Per Share
As for profitability, NeuroMetrix has a trailing twelve months EPS of $-0.42.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -20.47%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 4.7%, now sitting on 8.23M for the twelve trailing months.
Volume
Today’s last reported volume for NeuroMetrix is 15828 which is 65.66% below its average volume of 46093.
More news about NeuroMetrix (NURO).
